
Novavax Inc (NASDAQ:NVAX) shares are trading lower Tuesday. The stock fell to new 52-week lows early in the session, but has since recovered.
Novavax on Tuesday announced that its partner, Takeda, received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for its Nuvaxovid Intramuscular Injection for primary and booster immunization in individuals aged 18 and older. Nuvaxovid is Novavax' novel recombinant protein-based COVID-19 vaccine.